Navigation Links
Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the 'Investment in Innovation (In3) West' Conference on February 29, 2008 in Las Vegas, NV
Date:2/28/2008

MOUNTAIN VIEW, Calif., Feb. 28 /PRNewswire/ -- Cardiva Medical, Inc., a privately held medical device company and developer of the Boomerang Catalyst(TM) System announces that it will present the highlights of the Boomerang Catalyst II System on February 29 at 9:20am at the Medtech Insight/Windhover Information's "Investment In Innovation (In3) West" medical technology investment and partnering conference held at The Venetian in Las Vegas, NV.

The Boomerang Catalyst II System builds on the success of its predecessor, the Boomerang Catalyst System, by adding an additional pro-coagulant to the proprietary hemostatic material of the Catalyst System. These generations are the first vascular closure devices to achieve final hemostasis on diagnostic patients in the catheterization lab leaving absolutely nothing behind in the patient, thereby eliminating a major source of complications, device failures, and re-access challenges. Additionally, clinical results presented in October 2007 at the TCT meeting in Washington D.C. showed that patients required statistically significantly less bed rest than patients utilizing the gold standard of manual compression for closure of the arterial access site.

To date, the family of Boomerang devices has been used in more than 100,000 percutaneous catheterization procedures in the U.S. During these procedures, a catheter is threaded through the femoral artery to the site of vascular disease (most common is in the heart), where diagnosis and/or treatment (such as stenting or angioplasty) can be performed. Traditionally, doctors have used two primary methods to close the femoral artery puncture site: direct manual compression over the puncture site or one of the various implantable vascular closure devices, which use materials (such as collagen, sutures, or staples) to create a physical seal of the puncture site.

"The Catalyst II device promises to build upon the already impressive clinical achievements of its predecessor," commented Ron Smalling, MD, Interventional Cardiologist, St. John's, Joplin, MO. Dr. Smalling, who is a member of Cardiva's Medical Advisory Board, continued, "The ability to ambulate even faster than its predecessor while not leaving any material in the body is a significant advantage for patients, the hospital and the staff."

About Cardiva Medical, Inc.

Founded in July 2002, and headquartered in Mountain View, Calif., Cardiva Medical, Inc. is a privately held medical company focused on developing and commercializing devices which close the vascular access site with unsurpassed safety and ease-of-use. Cardiva's first product, the Boomerang Wire System, was approved in EU countries and in the US in 2004. Cardiva's second-generation product, the Boomerang Catalyst System, was approved in March 2007 and launched in July 2007. The enhanced Boomerang Catalyst, trade named as "Boomerang Catalyst II System" received 510(K) clearance in September 2007 and launched in January 2008. Cardiva was selected by Frost & Sullivan as the recipient of the 2006 Frost & Sullivan Award for Entrepreneurial Company in the U.S. angioplasty and vascular closure devices market. For additional information about Cardiva Medical, Inc. see our website at http://www.cardivamedical.com.

Cardiva, Boomerang and Boomerang Catalyst System are trademarks/registered trademarks of Cardiva Medical, Inc.

Media Contact:

Glenn Foy, President

Cardiva Medical, Inc.

Phone: 650.964.8900, x 215

Fax: 650.964.8911

glenn_foy@cardivamedical.com


'/>"/>
SOURCE Cardiva Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing
4. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
5. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
6. Medical, Behavioral Woes Can Drive Dogs to Bite
7. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
8. Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers Compensation and Leave Administration Services for Employers
9. Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome
10. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
11. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: